Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. In the U.S., Aerie developed and markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie has established development operations in Europe and Japan and a global manufacturing facility in Ireland. Aerie is expanding its ophthalmic pipeline with two clinical-stage retina programs in the U.S. and exploration of its proprietary library of small-molecule multi-kinase inhibitors.
Visit Aerie online
Aerie is providing an unrestricted education grant to the Advances in Glaucoma Research and Clinical Science Meeting 2019.